Transce3nd LLC Acquires Shares of 214 Danaher Co. (NYSE:DHR)

Transce3nd LLC bought a new position in Danaher Co. (NYSE:DHR) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 214 shares of the conglomerate’s stock, valued at approximately $49,000.

Other institutional investors have also recently made changes to their positions in the company. Kentucky Retirement Systems Insurance Trust Fund lifted its stake in Danaher by 11.6% in the fourth quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 21,233 shares of the conglomerate’s stock worth $4,874,000 after purchasing an additional 2,202 shares during the last quarter. ORG Partners LLC raised its holdings in shares of Danaher by 1,212.8% in the fourth quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock worth $636,000 after buying an additional 2,559 shares during the period. Generate Investment Management Ltd bought a new stake in shares of Danaher during the 4th quarter worth approximately $8,044,000. Compass Capital Management Inc. boosted its holdings in Danaher by 4.8% during the 4th quarter. Compass Capital Management Inc. now owns 237,922 shares of the conglomerate’s stock valued at $54,615,000 after acquiring an additional 10,994 shares during the period. Finally, Channing Global Advisors LLC grew its position in Danaher by 42.8% in the 4th quarter. Channing Global Advisors LLC now owns 5,666 shares of the conglomerate’s stock valued at $1,301,000 after acquiring an additional 1,698 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 3.8 %

NYSE:DHR opened at $192.06 on Wednesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The stock has a market capitalization of $137.27 billion, a P/E ratio of 36.38, a P/E/G ratio of 2.66 and a beta of 0.86. The company’s 50-day simple moving average is $201.41 and its 200-day simple moving average is $225.77. Danaher Co. has a fifty-two week low of $171.00 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.26. Danaher had a net margin of 16.33% and a return on equity of 10.82%. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. On average, equities analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a $0.32 dividend. This is a positive change from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 annualized dividend and a dividend yield of 0.67%. The ex-dividend date of this dividend is Friday, March 28th. Danaher’s dividend payout ratio (DPR) is presently 24.24%.

Insider Buying and Selling at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 11.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

DHR has been the subject of several research analyst reports. Robert W. Baird set a $231.00 target price on Danaher in a research report on Wednesday, April 16th. The Goldman Sachs Group upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $260.00 price objective for the company in a report on Friday, March 21st. Jefferies Financial Group dropped their target price on shares of Danaher from $260.00 to $230.00 and set a “buy” rating on the stock in a research note on Tuesday. JPMorgan Chase & Co. decreased their price target on shares of Danaher from $280.00 to $260.00 and set an “overweight” rating for the company in a research note on Tuesday. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $277.00 price objective (down previously from $299.00) on shares of Danaher in a research note on Thursday, January 30th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $271.55.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.